Dosimetry of internal emitters
- PMID: 15653648
Dosimetry of internal emitters
Abstract
Response and toxicity prediction is essential to rational implementation of cancer therapy. The biologic effects of radionuclide therapy are mediated via a well-defined physical quantity, the absorbed dose, which is defined as the energy absorbed per unit mass of tissue. The concepts, basic definitions, and different approaches to the clinical implementation of absorbed dose estimation are reviewed in this article. Ongoing efforts to improve the accuracy of dosimetry calculations are discussed, as well as studies examining the relationship between absorbed dose and response. Particular attention is placed on the marrow and kidney as dose-limiting organs. Finally, the potential role of radiobiologic modeling in helping to account for differences in dose rate and spatial distribution are reviewed. A treatment planning approach to radionuclide therapy will eventually require incorporation of biologic and radiobiologic considerations. Until such methods are developed and validated, absorbed dose remains an important variable--but still one of several--likely to predict response in an individual patient.
Similar articles
-
Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.J Nucl Med. 2005 Jan;46 Suppl 1:92S-8S. J Nucl Med. 2005. PMID: 15653657 Review.
-
Nuclear medicine dosimetry.Phys Med Biol. 2006 Jul 7;51(13):R187-202. doi: 10.1088/0031-9155/51/13/R12. Epub 2006 Jun 20. Phys Med Biol. 2006. PMID: 16790903 Review.
-
Dosimetry in Peptide radionuclide receptor therapy: a review.J Nucl Med. 2006 Sep;47(9):1467-75. J Nucl Med. 2006. PMID: 16954555 Review.
-
S-factor calculations for mouse models using Monte-Carlo simulations.Q J Nucl Med Mol Imaging. 2007 Dec;51(4):343-51. Epub 2007 Jun 1. Q J Nucl Med Mol Imaging. 2007. PMID: 17538523
-
Canine anatomic phantom for preclinical dosimetry in internal emitter therapy.J Nucl Med. 2008 Mar;49(3):446-52. doi: 10.2967/jnumed.107.046722. Epub 2008 Feb 20. J Nucl Med. 2008. PMID: 18287264
Cited by
-
Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody.Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):850-8. doi: 10.1007/s00259-006-0361-6. Epub 2007 Jan 30. Eur J Nucl Med Mol Imaging. 2007. PMID: 17262214
-
131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.J Nucl Med. 2010 Jul;51(7):1155-62. doi: 10.2967/jnumed.110.075176. Epub 2010 Jun 16. J Nucl Med. 2010. PMID: 20554734 Free PMC article.
-
Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2.EJNMMI Res. 2016 Dec;6(1):27. doi: 10.1186/s13550-016-0181-z. Epub 2016 Mar 17. EJNMMI Res. 2016. PMID: 26983637 Free PMC article.
-
A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy.Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1256-62. doi: 10.1016/j.ijrobp.2010.08.022. Epub 2010 Oct 13. Int J Radiat Oncol Biol Phys. 2011. PMID: 20950958 Free PMC article.
-
Radiation Safety Considerations and Clinical Advantages of α-Emitting Therapy Radionuclides.J Nucl Med Technol. 2022 Mar;50(1):10-16. doi: 10.2967/jnmt.121.262294. Epub 2021 Nov 8. J Nucl Med Technol. 2022. PMID: 34750237 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources